Skip to content

Visualizing uterine microvasculature using contrast-enhanced ultrasound for differentiating between uteri with adenomyosis, myoma, sarcoma, and no uterine disorders

Visualizing uterine microvasculature using contrast-enhanced ultrasound for differentiating between uteri with adenomyosis, myoma, sarcoma, and no uterine disorders - UteroVue

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56469
Enrollment
270
Registered
2023-04-13
Start date
2024-01-12
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenomyosis growth of inner lining uterus into uterine wall Contrast-enhanced ultrasound Microvasculature Gynaecology Uterine disorders

Interventions

Contrast enhanced ultrasonography of the uterus

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - >18 years of age - Have a uterus - Signed Informed Consent

Exclusion criteria

Exclusion criteria: - Pregnant women - Known allergy to SonoVue or any of its components - Severe heart disease or recent onset of cardiac rhythm disorders - Severe pulmonary hypertension - Use of angiogenesis inhibitor

Design outcomes

Primary

MeasureTime frame
Blood flow parameters (e.g. arrival time, peak intensity, wash-out time) obtained from time-intensity curves of adenomyosis, myomas and uteri without a disorder.

Secondary

MeasureTime frame
- Blood flow parameters of sarcomas - CEUS enhancement characteristics (e.g. homogeneity, order of enhancement, echogenicity) of adenomyosis, fibroids, sarcoma and uteri without disorders - Diagnostic performance (sensitivity, specificity and diagnostic accuracy) of detecting uterine disorder based on: o CEUS classification model for adenomyosis o CEUS classification model for sarcomas o Conventional ultrasound (assessment of the gynecologist) o MRI (assessment of the radiologist) o Histology (assessment of the pathologist) o Combination of all diagnostic tests used in the patient, including clinical presentation (assessment of the gynecologist)

Countries

Belgium, Netherlands

Contacts

Public ContactJ.A.F. Huirne

Amsterdam UMC

gyn_benigne@amsterdamumc.nl0205669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026